Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Infect Dis Clin North Am. 2020 Sep 30;34(4):773–819. doi: 10.1016/j.idc.2020.05.001

Table 7.

Clinical indications for the use of imipenem-cilastatin-relebactam

Indication Indicated Bacteria Patient Population Clinical Trials
cIAI Enterobacter cloacae, E coli, K aerogenes, K pneumoniae, and P aeruginosa Adult RESTORE- IMI 1182
NCT02452047
cUTI, including pyelonephritis Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, C freundii, Enterobacter cloacae, E coli, Fusobacterium nucleatum, K aerogenes, K oxytoca, K pneumoniae, Parabacteroides distasonis, and P aeruginosa Adult RESTORE-IMI 1182
NCT02452047

Data from Merck & Co., Inc. RECARBRIO (Imipenem, Cilastatin, and Relebactam) for Injection, for Intravenous Use. Whitehouse Station, NJ 08889 USA.; 2019.